Halyard Health Inc (HYH) Receives $47.00 Average Target Price from Analysts
Shares of Halyard Health Inc (NYSE:HYH) have earned an average rating of “Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $49.33.
HYH has been the topic of a number of research reports. ValuEngine raised Halyard Health from a “hold” rating to a “buy” rating in a report on Wednesday, February 28th. Zacks Investment Research lowered Halyard Health from a “buy” rating to a “hold” rating in a report on Wednesday, January 3rd. Finally, TheStreet raised Halyard Health from a “c+” rating to a “b” rating in a report on Monday, December 4th.
Shares of Halyard Health (NYSE:HYH) traded down $0.64 during midday trading on Wednesday, reaching $46.09. The company’s stock had a trading volume of 141,009 shares, compared to its average volume of 316,519. The company has a current ratio of 2.98, a quick ratio of 2.74 and a debt-to-equity ratio of 0.45. Halyard Health has a 52-week low of $35.24 and a 52-week high of $50.99. The firm has a market cap of $2,192.57, a price-to-earnings ratio of 20.14, a price-to-earnings-growth ratio of 2.75 and a beta of 1.60.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Xact Kapitalforvaltning AB acquired a new stake in shares of Halyard Health during the 4th quarter worth $250,000. MetLife Investment Advisors LLC bought a new stake in shares of Halyard Health during the 4th quarter worth $2,332,000. Macquarie Group Ltd. lifted its position in shares of Halyard Health by 103.0% during the 4th quarter. Macquarie Group Ltd. now owns 859,281 shares of the medical instruments supplier’s stock worth $39,681,000 after buying an additional 435,935 shares during the last quarter. Vident Investment Advisory LLC raised its position in Halyard Health by 6.5% in the fourth quarter. Vident Investment Advisory LLC now owns 67,997 shares of the medical instruments supplier’s stock valued at $3,140,000 after purchasing an additional 4,147 shares during the last quarter. Finally, Jane Street Group LLC raised its position in Halyard Health by 88.0% in the fourth quarter. Jane Street Group LLC now owns 8,808 shares of the medical instruments supplier’s stock valued at $407,000 after purchasing an additional 4,124 shares during the last quarter. 90.45% of the stock is currently owned by institutional investors.
Halyard Health Company Profile
Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.
Receive News & Ratings for Halyard Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halyard Health and related companies with MarketBeat.com's FREE daily email newsletter.